JP2021519302A5 - - Google Patents
Info
- Publication number
- JP2021519302A5 JP2021519302A5 JP2020551836A JP2020551836A JP2021519302A5 JP 2021519302 A5 JP2021519302 A5 JP 2021519302A5 JP 2020551836 A JP2020551836 A JP 2020551836A JP 2020551836 A JP2020551836 A JP 2020551836A JP 2021519302 A5 JP2021519302 A5 JP 2021519302A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- subject
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147297A JP7719135B2 (ja) | 2018-03-26 | 2023-09-12 | 微小残存がんを治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648166P | 2018-03-26 | 2018-03-26 | |
| US62/648,166 | 2018-03-26 | ||
| PCT/US2019/024097 WO2019191115A1 (en) | 2018-03-26 | 2019-03-26 | Methods of treating minimal residual cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147297A Division JP7719135B2 (ja) | 2018-03-26 | 2023-09-12 | 微小残存がんを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519302A JP2021519302A (ja) | 2021-08-10 |
| JP2021519302A5 true JP2021519302A5 (enExample) | 2022-04-04 |
Family
ID=68060400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551836A Pending JP2021519302A (ja) | 2018-03-26 | 2019-03-26 | 微小残存がんを治療する方法 |
| JP2023147297A Active JP7719135B2 (ja) | 2018-03-26 | 2023-09-12 | 微小残存がんを治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147297A Active JP7719135B2 (ja) | 2018-03-26 | 2023-09-12 | 微小残存がんを治療する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210121527A1 (enExample) |
| EP (1) | EP3775171B1 (enExample) |
| JP (2) | JP2021519302A (enExample) |
| KR (1) | KR102897382B1 (enExample) |
| CN (1) | CN112166187B (enExample) |
| AU (1) | AU2019243443B2 (enExample) |
| BR (1) | BR112020019023A2 (enExample) |
| CA (1) | CA3095156A1 (enExample) |
| EA (1) | EA202092282A1 (enExample) |
| ES (1) | ES2975770T3 (enExample) |
| IL (2) | IL277568A (enExample) |
| MX (1) | MX2020009922A (enExample) |
| WO (1) | WO2019191115A1 (enExample) |
| ZA (1) | ZA202005723B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156888A1 (en) | 2017-02-24 | 2018-08-30 | Biothera Pharmaceuticals, Inc. | Beta glucan immunopharmacodynamics |
| RS65914B1 (sr) | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
| CN114585606A (zh) * | 2019-08-29 | 2022-06-03 | 希伯塞尔股份有限公司 | 抑制perk的化合物 |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| CN113604436A (zh) * | 2021-08-11 | 2021-11-05 | 清华大学深圳国际研究生院 | 一种肿瘤内分泌药物诱导的休眠或复发细胞株的构建方法 |
| WO2024077099A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030933A2 (en) * | 2003-09-24 | 2005-04-07 | Genera Doo | Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer |
| AU2009219437B2 (en) * | 2008-02-25 | 2014-10-16 | Nestec S.A. | Drug selection for breast cancer therapy using antibody-based arrays |
| RS65914B1 (sr) * | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
-
2019
- 2019-03-26 CA CA3095156A patent/CA3095156A1/en active Pending
- 2019-03-26 AU AU2019243443A patent/AU2019243443B2/en active Active
- 2019-03-26 MX MX2020009922A patent/MX2020009922A/es unknown
- 2019-03-26 KR KR1020207030641A patent/KR102897382B1/ko active Active
- 2019-03-26 CN CN201980035263.7A patent/CN112166187B/zh active Active
- 2019-03-26 JP JP2020551836A patent/JP2021519302A/ja active Pending
- 2019-03-26 WO PCT/US2019/024097 patent/WO2019191115A1/en not_active Ceased
- 2019-03-26 US US17/041,006 patent/US20210121527A1/en active Pending
- 2019-03-26 BR BR112020019023-3A patent/BR112020019023A2/pt unknown
- 2019-03-26 EA EA202092282A patent/EA202092282A1/ru unknown
- 2019-03-26 ES ES19774552T patent/ES2975770T3/es active Active
- 2019-03-26 EP EP19774552.4A patent/EP3775171B1/en active Active
-
2020
- 2020-09-15 ZA ZA2020/05723A patent/ZA202005723B/en unknown
- 2020-09-23 IL IL277568A patent/IL277568A/en unknown
-
2021
- 2021-09-12 IL IL286297A patent/IL286297A/en unknown
-
2023
- 2023-09-12 JP JP2023147297A patent/JP7719135B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519302A5 (enExample) | ||
| AU2018233032B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
| US12485174B2 (en) | HDAC6-activated macrophages, compositions, and uses thereof | |
| CN110536703B (zh) | 使用抗axl抗体-药物缀合物的组合疗法 | |
| BR112020008888A2 (pt) | terapias de combinação | |
| WO2024048541A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2019191115A4 (en) | Methods of treating minimal residual cancer | |
| WO2015105926A1 (en) | Polynucleotides for the in vivo production of antibodies | |
| EP3600326B1 (en) | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | |
| JP2022527081A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| JP2024028888A (ja) | 自家がんワクチン | |
| TWI882048B (zh) | 預防癌症復發的組成物及方法 | |
| US20240408071A1 (en) | Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer | |
| US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
| Chakraborty et al. | AZD4625 is a potent and selective inhibitor of KRASG12C | |
| WO2016142486A1 (en) | Methods and compositions for the treatment of anti-angiogenic resistant cancer | |
| WO2024130696A1 (zh) | 精胺在预防和治疗炎症性疾病中的用途 | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| De Lartigue | Rising to the Therapeutic challenge of Head and Neck Cancer | |
| US12429477B2 (en) | Methods and agents for determining patient status | |
| Lim et al. | Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance | |
| Nigam et al. | Epigenetic silencing by SMYD3 represses tumor intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck | |
| CN121889151A (zh) | Wee1抑制剂和pkmyt1抑制剂的组合 | |
| CN119930754A (zh) | 基于线粒体膜Atad3a-VDAC1互作的小分子肽开发在肺癌治疗中的应用 | |
| Chen et al. | P2. 10A. 03 RESOLUTION: Phase II Study of Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in Patients with HER2 Alteration Advanced NSCLC |